1. Unit startpage
  2. Employees
  3. Richard Alan Engh
Bilde av Engh, Richard Alan
Bilde av Engh, Richard Alan
Institutt for kjemi richard.engh@uit.no +4777644073 Tromsø You can find me here

Richard Alan Engh

Job description

Professor, Biomolekylær og strukturkjemi, Norstruct

  • Philip Ben, Fredrik G., Martin, Mitchell, Eric, Johanna Ulrica et al.:
    Label-free measurement of antimicrobial peptide interactions with lipid vesicles and nanodiscs using microscale thermophoresis
    Scientific Reports 2023 DOI / ARKIV
  • Wenche, Ulli, Richard Alan, Melissa R., Ilya, Alberto C. S. et al.:
    Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome
    Pharmaceuticals 2021 DOI / ARKIV / FULLTEKST
  • Robin, Jian, Friedrich W., Susan, Richard Alan :
    Drugging the Undruggable: How Isoquinolines and PKA Initiated the Era of Designed Protein Kinase Inhibitor Therapeutics
    Biochemistry 2021 DOI
  • Krzysztof, Maria, Arkadiusz, Grazyna, Anna, Halina et al.:
    Two SnRK2-Interacting Calcium Sensor Isoforms Negatively Regulate SnRK2 Activity by Different Mechanisms
    Plant Physiology 2020 DOI / ARKIV
  • Kazi Asraful, Osman, Richard Alan :
    Inhibitor binding of mutants of protein kinase A with GGGXXG and GXGXXA glycine-rich loop motifs
    Journal of Molecular Recognition 2020 DOI
  • Balmukund, Richard Alan :
    Comparative conformational analyses and molecular dynamics studies of glycylglycine methyl ester and glycylglycine N -methylamide
    RSC Advances 24. janvier 2018 DOI / ARKIV / FULLTEKST
  • Balmukund, John Sigurd Mjøen, Richard Alan :
    Density Functional Studies on Secondary Amides: Role of Steric Factors in Cis/Trans Isomerization
    Molecules 25. septembre 2018 DOI / ARKIV / FULLTEKST
  • Anna Lucja, Wang, Diana, Yao, Xianming, Hwan Geun et al.:
    Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors
    Journal of Medicinal Chemistry 2018 DOI / ARKIV
  • Clemens Joachim, Franz, Richard Alan, Tor :
    Dynamical models of mutated chronic myelogenous leukemia cells for a postimatinib treatment scenario: Response to dasatinib or nilotinib therapy
    PLOS ONE 2017 DOI / ARKIV
  • Dilip, Osman, Franz, Richard Alan :
    Data driven polypharmacological drug design for lung cancer: Analyses for targeting ALK, MET, and EGFR
    Journal of Cheminformatics 2017 DOI / ARKIV
  • Balmukund, Marte, John Sigurd Mjøen, Jeanette hammer, Richard Alan :
    Biofocussed chemoprospecting: An efficient approach for drug discovery
    Chemical Biology and Drug Design (CB&DD) 13. juin 2017 DOI / FULLTEKST
  • Balmukund, John Sigurd Mjøen, Richard Alan :
    Cis/Trans Isomerization in Secondary Amides: Reaction Paths, Nitrogen Inversion and Relevance to Peptidic Systems
    Journal of Physical Chemistry A 15. août 2017 DOI / FULLTEKST
  • Taavi, Erki, Birgit, Ganesh babu, Gerda, Alexander et al.:
    Bifunctional ligands for inhibition of tight-binding protein-protein interactions
    Bioconjugate chemistry 2016 DOI
  • Ulli, Wenche, Bjørn Olav, Johan, Frederick Alan, Richard Alan et al.:
    Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules
    Journal of Medicinal Chemistry 2016 DOI
  • Osman A.B.S.M., Balmukund, Dilip, Kazi Asraful, Peter, Ulli et al.:
    Assessing protein kinase target similarity: Comparing sequence, structure, and cheminformatics approaches
    Biochimica et Biophysica Acta - Proteins and Proteomics 2015 DOI / FULLTEKST
  • Birgit S., Leo A., Kazi Asraful, Bjarte Aarmo, Oliver, Michael et al.:
    Addressing the Glycine-Rich Loop of Protein Kinases by a Multi-Facetted Interaction Network: Inhibition of PKA and a PKB Mimic
    Chemistry - A European Journal 18. novembre 2015 DOI
  • Eric, Stefan, Richard Alan, Henrik, Thibault, Benoit et al.:
    Perspective on computational and structural aspects of kinase discovery from IPK2014
    Biochimica et Biophysica Acta - Proteins and Proteomics 2015 DOI
  • Marina, espen, Richard Alan, Ulli :
    The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A-PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine.
    Acta Crystallographica Section D: Biological Crystallography 2015 DOI / ARKIV
  • Ulli, Jonas, Wenche, Frederick Alan, Richard Alan, John Sigurd :
    Luciferin and derivatives as a DYRK selective scaffold for the design of protein kinase inhibitors
    European Journal of Medicinal Chemistry 2015 DOI
  • Anna L, Anna K., Christoph, Stefanie, Richard Alan, Samantha et al.:
    Inhibition of aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and aurora kinases R763/ AS703569 and PHA-739358 in BCR-ABL transformed cells
    PLOS ONE 2014 DOI / ARKIV
  • Osman A.B.S.M., Dilip, Richard Alan :
    Evaluating the Predictivity of Virtual Screening for Abl Kinase Inhibitors to Hinder Drug Resistance
    Chemical Biology and Drug Design (CB&DD) 2013 DOI / ARKIV
  • Alexander, Kenneth, Richard Alan :
    Anomalous dispersion analysis of inhibitor flexibility: a case study of the kinase inhibitor H-89
    Acta Crystallographica. Section F : Structural Biology and Crystallization Communications 2012 DOI / ARKIV
  • Kine Østnes, Jeanette hammer, Trine, Richard Alan, Johan, Anne-Marie et al.:
    Antitumoral and Mechanistic Studies of Ianthelline Isolated from the Arctic Sponge Stryphnus fortis
    Anticancer Research 2012
  • espen, Bjarte Aarmo, Alexander, Osman A.B.S.M., Ulli, Taiana Maia De et al.:
    Structural origins of AGC protein kinase inhibitor selectivities: PKA as a drug discovery tool
    Biological chemistry 2012 DOI
  • Alexander, Taiana Maia De, Dirk, Richard Alan :
    Mutants of protein kinase A that mimic the ATP-binding site of Aurora kinase
    Biochemical Journal 2011 DOI
  • Rama Krishna, Nikolas von, Natalie, Christian, Richard Alan, Justus :
    Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib
    PLOS ONE 2011 DOI
  • N. von, S.P., Richard Alan, Taiana Maia De, S., espen et al.:
    The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro
    Oncogene 2011 DOI
  • ME, SM, FA, RW, V, J et al.:
    Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase
    Journal of Medicinal Chemistry 2011 DOI
  • Taiana Maia De, Rafi, Richard Alan :
    VX680 Binding in Aurora A: pi-pi Interactions Involving the Conserved Aromatic Amino Acid of the Flexible Glycine-Rich Loop
    Journal of Physical Chemistry A 2011 DOI
  • Ulli, espen, Kenneth, Tom Egil, Jorunn B, Richard Alan :
    p38 alpha MAP Kinase Dimers with Swapped Activation Segments and a Novel Catalytic Loop Conformation
    Journal of Molecular Biology (JMB) 2011 DOI
  • Osman A.B.S.M., Richard Alan :
    Protein kinase inhibition of clinically important staurosporine analogues
    Natural product reports (Print) 2010 DOI
  • Alexander, Jevgenia, Darja, Erki, Asko, Richard Alan et al.:
    Diversity of Bisubstrate Binding Modes of Adenosine Analogue-Oligoarginine Conjugates in Protein Kinase A and Implications for Protein Substrate Interactions
    Journal of Molecular Biology (JMB) 2010 DOI
  • N von, Richard Alan, espen, J, C, J :
    FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
    Cancer Research 2009 DOI
  • Richard Alan :
    Diversity of target profiles for ABL kinase inhibitors
    2019
  • Richard Alan :
    Protein structures "in crystallo" and "in vivo: do they match? Are they useful?
    2018
  • Richard Alan :
    Prospects for linking TKI protein kinase inhibition profiles to CML modelling parameters
    2017
  • Marc, Osman, Richard Alan, Jørn H :
    Bioactive Heterocycle Libraries for Anticancer Drug Discovery - Development of Covalent Binding TK Inhibitors
    2016
  • Marina, espen, Richard Alan, Ulli :
    The structure of a dual-specificity tyrosine phosphorylation-regulated kinase 1A-PKC412 complex reveals disulfide-bridge formation with the anomalous catalytic loop HRD(HCD) cysteine.
    2016
  • Richard Alan :
    Unpredictable protein kinase flexibility: curse or blessing for inhibitor discovery?
    2016
  • Kazi Asraful, Ulli, Richard Alan :
    Static and dynamic interactions between the glycine-rich loop of protein kinases and ATP site inhibitors
    2016
  • Balmukund, Osman, Richard Alan :
    Practical Applications of Informatics Tools to Identify Drug Targets for Novel Compounds from Bio- and Chemoprospecting
    2016
  • Balmukund, Richard Alan :
    PKA to Rho Kinase (ROCK): Assessing Structural Similarity via Surrogates
    2015
  • Marc, Osman A.B.S.M., Richard Alan, Jørn H :
    Bioactive Heterocycle Libraries for Anticancer Drug Discovery
    2015
  • Kazi Asraful, Richard Alan :
    The Glycine Rich Loop As Selectivity Determinant For Protein Kinase Inhibitors
    2015
  • Kazi Asraful, Richard Alan :
    Selectivity Determinants of Aurora Kinases
    2015
  • Balmukund, John Sigurd Mjøen, Richard Alan :
    Design and Synthesis of diverse Piperazine-2,5-diones and their uncyclized analogues as potential kinase inhibitors
    2013
  • espen, Ole Morten, Richard Alan, Franz :
    Fra Mutasjon til Medisin
    2013
  • Balmukund, Jørn H, Richard Alan :
    Design and Synthesis of Tartaric Acid Bisamides: Focus on Kinase Inhibition
    2013
  • Franz, Thomas, Kimmo, Richard Alan, ingvild, Jacqueline et al.:
    Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients
    Leukemia 2012 DOI
  • RK, N. von, N, C., Richard Alan, J. :
    Irreversible inhibitors overcome lapatinib resistance due to ERBB2 kinase domain mutations
    Onkologie (Basel) 2011

    • The 50 latest publications is shown on this page. See all publications in Cristin here →

    Publikasjoner utenom Cristin

     

    fra PubMed

    fra Google Scholar

     

     

     

    Research interests

    Enzym-ligand vekselvirkninger

    Drug design

    Cheminformatics

     


    Member of research group

    Protein Kinase Biophysics   English content Biological Chemistry and Bioinformatics   English content
    Forskningsparken 3 G222


    Click for bigger map